Rita De Sanctis

Humanitas University
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (39)

Patients and methods we retrospectively collected data of patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i) aiming to describe the patterns of post-progression outcomes. Results Among 452 evaluable patients 325 were treated in the first-line setting. Median progression-free survival (mPFS) was 22.8 months overall and 29.7 months in patients treated in first-line setting. Factors associated with outcomes in multivariate analysis were the line of CDK4/6i therapy, de novo vs recurrent disease, visceral vs bone-only metastases, and primary endocrine resistance. A total of 300 patients progressed and 250 overall and 156 in the first-line cohort received a subsequent treatment. Visceral progression and CDK4/6i duration <12 months were associated with a higher likelihood of receiving anthracycline or taxanes (AT) as compared to ET ±everolimus (EET). Post-progression PFS (PPFS) and post-progression OS (PPOS) were statistically significantly better with EET and capecitabine (C) over AT overall and in patients with visceral progression. Multivariate analysis confirmed a significant advantage for EET and C, while visceral progression retained a significant impact only on PPOS. After progression to the first post-CDK4/6i treatment C obtained a significant better PPOS as compared to other treatments. Conclusion We showed in a large real-world series that most patients with HR+/HER2− ABC failing CDK4/6i and ET unselected for the occurrence of molecular mutations retain endocrine sensitivity and may benefit of a subsequent ET ± a targeted therapy delaying the need for chemotherapy regardless of site of progression and prior CDK4/6i therapy duration.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background/objectives: Pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is a solid indicator of favourable prognosis, potentially also being useful for more conservative patient management. We aim to explore the potential of [18F]FDG PET/CT as a non-invasive method to predict response to NAC. Methods: In this prospective, observational cohort study, we enrolled BC patient candidates for NAC who underwent baseline and preoperative [18F]FDG PET/CT. NAC response was determined using final histopathology. PET images were assessed qualitatively and semi-quantitatively, and the findings correlated with NAC response. Results: In total, 133 BC patients were included. The visual analysis of preoperative PET/CT detected residual disease (RD) with high specificity (>93%) and moderate sensitivity, based on pCR/RD classification and RCB index. Semiquantitative measures (SUVmax, TBR) were significantly higher in non-responders across the classification methods (p < 0.001 for all). Conclusions: These findings highlight the potential of preoperative [18F]FDG PET/CT as a complementary tool for identifying excellent responders to NAC across BC subtypes or response criteria. This could inform personalised treatment and potentially allow for surgery to be omitted in selected patients.

Year:

2025

Backgrounds: Neoadjuvant therapy (NAT) is a cornerstone in the management of breast cancer (BC), enabling tumor downstaging and improved surgical options. Methods: This study retrospectively analyzed 607 BC patients treated with NAT and surgery at IRCCS Humanitas Research Hospital, Milan, Italy, to compare long-term oncologic outcomes of breast-conserving surgery (BCS) versus mastectomy. Patient demographics, tumor characteristics, and treatment details were analyzed using descriptive statistics, logistic regression, and Cox proportional hazards models. Results: Of the 607 patients, 54.7% underwent BCS, and 45.3% had mastectomy. BCS was associated with significantly superior 10-year outcomes compared to mastectomy, including disease-free survival (DFS, 75.2% vs. 71.1%, p = 0.001), distant DFS (75.2% vs. 71.1%, p = 0.001), overall survival (OS, 82.9% vs. 78.1%, p = 0.002), and BC-specific survival (BCSS, 87.7% vs. 83.1%, p = 0.001). Pathologic complete response (pCR) emerged as a protective factor across all endpoints, while mastectomy was independently associated with worse BCSS (HR: 2.068, 95% CI: 1.016–4.210, p = 0.045). Conclusions: Our findings demonstrate the oncologic safety and potential superiority of BCS over mastectomy in NAT-treated BC patients, highlighting the importance of individualized surgical decision-making to optimize survival outcomes.

Year:

2025

Chronic migraine (CM) is a highly disabling condition, affecting about 2% of the global population. Non-pharmacological treatments can be optimal for their non-invasive nature. This prospective, randomized, double-blind, controlled trial aimed to test the efficacy of therapeutic neuroscience education (TNE) in CM. Early response biomarkers were also evaluated. A total of 80 CM patients were consecutively enrolled and randomly allocated to TNE or a general education program. Treatment effectiveness was evaluated at baseline (T1) and 2 months after the end of treatment (T4). We collected the responses to disability and comorbidity questionnaires at the start (T1) and end of treatment (T3, 10 weeks after start). Early response biomarkers were evaluated at screening (T0) and mid-way through the process (T2, 5 weeks after start). We expected that TNE would provide a greater benefit than the general education program, which served as the primary outcome of this study. We also expected that a change in clinical and neurophysiological measures could potentially occur, reflecting plasticity-induced reorganization and predicting clinical response. This is the first study selectively exploring the effect of TNE as a standalone treatment for CM. A new, effective treatment regime without interactions with other medication could be of great interest as an addition to migraine therapeutic strategies.

Year:

2025

Year:

2025

The NATALEE trial expanded the use of adjuvant cyclin-dependent kinase 4/6 inhibitors beyond the MonarchE trial’s criteria for early breast cancer (eBC). We conducted a retrospective analysis comparing a large real-world (RW) cohort of 762 consecutive eBC patients with those enrolled in the NATALEE and MonarchE randomized controlled trials (RCTs) to evaluate differences in eligibility. Our analysis revealed that 41.7% of RW patients met NATALEE’s eligibility criteria, significantly more than the 21.8% who met MonarchE’s criteria, reflecting NATALEE’s broader indication. Real-world patients were older, had less advanced tumors, and were less likely to be treated with adjuvant chemotherapy compared to the RCT populations. None of the RW patients was deemed eligible for ribociclib based solely on high genomic risk. These findings underscore significant differences in clinical characteristics and potential treatment eligibility, highlighting the need for critical assessment of RCTs results in clinical practice.

Year:

2025

PURPOSE Real-world data (RWD) are critical for breast cancer (BC) research but are limited by privacy concerns, missing information, and data fragmentation. This study explores synthetic data (SD) generated through advanced generative models to address these challenges and create harmonized longitudinal data sets. METHODS A data set of 1052 patients with human epidermal growth factor receptor 2–positive and triple-negative BC from the Informatics for Integrating Biology and the Bedside (i2b2) platform was used. Advanced generative models, including generative adversarial networks (GANs), variational autoencoders (VAEs), and language models (LMs), were applied to generate synthetic longitudinal data sets replicating disease progression, treatment patterns, and clinical outcomes. The Synthethic Validation Framework (SAFE) powered by Train was used to evaluate the fidelity, utility, and privacy. SD were tested across three settings: (1) integration with i2b2 for privacy-preserving data sets; (2) multistate disease modeling to predict clinical outcomes; and (3) generation of synthetic control groups for clinical trials. RESULTS The synthetic data sets exhibited high fidelity (score 0.94) and ensured privacy, with temporal patterns validated through time-series analyses and Uniform Manifold Approximation and Projection embeddings. In setting A, SD accurately mirrored RWD on the i2b2 platform while maintaining privacy. In setting B, incorporating SD improved the predictive performance of a multistate disease progression model, increasing the C-index by up to 10%. In setting C, SD replicated the end points of the APT trial, demonstrating its feasibility for generating synthetic control arms with preserved statistical properties of the real data set. CONCLUSION AI-generated longitudinal SD effectively address key challenges in RWD use in BC. This approach can improve translational research and clinical trial design while ensuring robust privacy protection. Integration with platforms such as i2b2 highlights their scalability and potential for broader applications in oncology.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (23)

Valentina Guarneri

Associate Professor

University of Padova

ITALY
View details

Armando Santoro

Professore

Humanitas University

ITALY
View details

Arturo Chiti

Director

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia

ITALY
View details

Luca Lanino

Yale University

UNITED STATES
View details

Riccardo Borroni

Docenti di ruolo di IIa fascia

Humanitas University

ITALY
View details

Lidija Antunovic

Deputy director

IRCCS Humanitas Research Hospital

ITALY
View details

Valentina Vaira

University of Milan

ITALY
View details

Martina Sollini

Associate Professor in Diagnostic Imaging and Radiotherapy

Vita-Salute San Raffaele University

ITALY
View details

Corrado Tinterri

Head of the Department

Humanitas University

ITALY
View details

Gaia Griguolo

University of Padua

ITALY
View details

Matteo Castaldo

Aalborg University

DENMARK
View details

Fabrizia Gelardi

Vita-Salute San Raffaele University

ITALY
View details

Alberto Zambelli

Associate Professor

University of Milano-Bicocca

ITALY
View details

Elisa Agostinetto

Institut Jules Bordet

BELGIUM
View details

Jacopo Lanzone

M.D

Ospedale San Raffaele

ITALY
View details

Giuseppe Penna

Staff Scientist

IRCCS Humanitas Research Hospital

ITALY
View details

Matteo Fassan

Docenti di ruolo di Ia fascia

University of Padova

ITALY
View details

Maria Vittoria Dieci

Assistant professor (Ricercatore tempo determinato tipo B)

University of Padova

ITALY
View details

Federica Giugliano

Institut Gustave Roussy

FRANCE
View details

ALESSIA ARTESANI

Assistant Professor

Humanitas University

ITALY
View details

Damiano Gentile

Breast Surgeon

IRCCS Humanitas Research Hospital

ITALY
View details

Simone Sarasso

Docenti

University of Milan

ITALY
View details

Simone Di Maria Grimaldi

Humanitas University

ITALY
View details